Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174370
Title: | Mycolicibacterium brumae is a safe and non-toxic immunomodulatory agent for cancer treatment |
Author: | Bach Griera, Marc Campo Pérez, Víctor Barbosa, Sandra Traserra, Sara Guallar Garrido, Sandra Moya Andérico, Laura Herrero Abadía, Paula Luquin, Marina Rabanal Prados, Rosa Ma. (Rosa Maria) Torrents Serra, Eduard Julián, Esther |
Keywords: | Àcids grassos Càncer Fatty acids Cancer |
Issue Date: | 25-Apr-2020 |
Publisher: | MDPI |
Abstract: | Intravesical Mycobacterium bovis Bacillus Calmette-Guérin (BCG) immunotherapy remains the gold-standard treatment for non-muscle-invasive bladder cancer patients, even though half of the patients develop adverse events to this therapy. On exploring BCG-alternative therapies, Mycolicibacterium brumae, a nontuberculous mycobacterium, has shown outstanding anti-tumor and immunomodulatory capabilities. As no infections due to M. brumae in humans, animals, or plants have been described, the safety and/or toxicity of this mycobacterium have not been previously addressed. In the present study, an analysis was made of M. brumae- and BCG-intravenously-infected severe combined immunodeficient (SCID) mice, M. brumae-intravesically-treated BALB/c mice, and intrahemacoelic-infected-Galleria mellonella larvae. Organs from infected mice and the hemolymph from larvae were processed to count bacterial burden. Blood samples from mice were also taken, and a wide range of hematological and biochemical parameters were analyzed. Finally, histopathological alterations in mouse tissues were evaluated. Our results demonstrate the safety and non-toxic profile of M. brumae. Di erences were observed in the biochemical, hematological and histopathological analysis between M. brumae and BCG-infected mice, as well as survival curves rates and colony forming units (CFU) counts in both animal models. M. brumae constitutes a safe therapeutic biological agent, overcoming the safety and toxicity disadvantages presented by BCG in both mice and G. mellonella animal models. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/vaccines8020198 |
It is part of: | Vaccines, 2020, vol. 8(2), num. 198 |
URI: | http://hdl.handle.net/2445/174370 |
Related resource: | https://doi.org/10.3390/vaccines8020198 |
ISSN: | 2076-393X |
Appears in Collections: | Articles publicats en revistes (Genètica, Microbiologia i Estadística) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
701803.pdf | 2.64 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License